KRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
KORU Medical Systems Inc (KRMD) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the stock is currently oversold, with a low RSI indicating a potential rebound, the lack of significant positive catalysts, weak financial performance, and absence of Intellectia Proprietary Trading Signals suggest holding off on investment until further clarity or improvement in fundamentals.
The stock is currently oversold with an RSI of 13.541, indicating potential for a rebound. However, the MACD is negatively expanding (-0.117), and the price is below the pivot level of 5.031, suggesting bearish momentum. Moving averages are converging, signaling indecision in the market.
Analysts have raised price targets recently (Lake Street to $8 and Canaccord to $6), indicating optimism about future growth. The upcoming 510K submission for oncology indication is expected to be a meaningful catalyst.
Weak financial performance in Q3 2025, with net income dropping 50.79% YoY and EPS declining by 33.33%. Gross margin also fell by 3.88%. No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q3 2025, revenue increased by 27.17% YoY to $10.4M, but net income dropped significantly to -$777,966 (-50.79% YoY). EPS declined to -0.02 (-33.33% YoY), and gross margin decreased to 58.26% (-3.88% YoY).
Analysts maintain a Buy rating with raised price targets (Lake Street: $8, Canaccord: $6), citing expected growth acceleration in 2026 and revenue upside potential.
